Letrolan

Letrozole, the active ingredient in Letrolan, is a aromatase inhibitor presented as an oral tablet for oral use. It is used to treat postmenopausal estrogen receptor‑positive breast cancer, helping to slow tumor growth and improve survival outcomes.

GNH USA supplies Letrolan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole belongs to the aromatase inhibitor class and is employed in the management of hormone‑dependent breast cancer.

- Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor progression and disease recurrence. - Adjuvant therapy for early‑stage hormone‑receptor‑positive breast cancer: lowers risk of cancer returning after surgery. - Metastatic hormone‑receptor‑positive breast cancer: improves overall survival and delays disease spread.

Letrozole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in limbs and joints. - Fatigue: persistent tiredness. - Nausea: upset stomach and possible vomiting. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk due to bone density loss. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reaction: rash, swelling, anaphylaxis. - QT interval prolongation: cardiac rhythm disturbance. - Hypercholesterolemia: significant rise in cholesterol levels.

Before initiating Letrozole therapy, several safety considerations are essential.

- Pregnancy contraindication: avoid use in pregnant women; teratogenic risk. - Breastfeeding prohibition: do not use while nursing; drug passes into milk. - Bone health monitoring: assess bone mineral density periodically. - Liver function assessment: check hepatic enzymes before and during treatment. - Lipid profile surveillance: monitor cholesterol levels regularly. - Avoid use in premenopausal women: efficacy not established. - Store at ambient temperature: keep in original packaging, protect from moisture.

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect reduces therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower letrozole plasma levels. - Strong CYP2A6 inhibitors (e.g., methoxsalen): increase letrozole exposure and toxicity. - Estrogen replacement therapy: diminishes aromatase inhibition.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Statins (especially simvastatin): heightened risk of myopathy. - SSRIs (e.g., fluoxetine): may modestly affect QT interval. - Anticonvulsants (e.g., phenytoin): may alter hormone metabolism. - Proton pump inhibitors: occasional effect on absorption, monitor clinical response.